ImmuCell Corporation
Last updated September 27, 2026
Organization details
- Legal name
- ImmuCell Corporation
- Ownership
- Public
- Status
- Active
- SIC code
- 2835 — In Vitro & In Vivo Diagnostic Substances
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Portland
- Headquarters state / province
- Maine
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ICCC
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000811641
- EIN
- 01-0382980
Board of directors
-
Anthony DiMarco · DirectorSince 2026
-
Bobbi Jo Brockmann · Director · VP of Sales and MarketingSince 2026
-
Boekhorst Paul Francis Olivier Te · Director · President and CEOSince 2025
-
Bryan K. Gathagan · DirectorSince 2023
-
David Cunningham · DirectorSince 2023
-
David Scott Tomsche · DirectorSince 2023
-
Gilles Guillemette · DirectorSince 2026
-
Gloria F. Basse · DirectorSince 2020
-
Kathy Turner V · DirectorSince 2026
-
Michael F. Brigham · DirectorSince 2026
-
Paul R. Wainman · DirectorSince 2023
-
Steven T. Rosgen · DirectorSince 2023
-
Timothy C. Fiori · Director · Chief Financial OfficerSince 2026
Chief executives
Boekhorst Paul Francis Olivier Te
· President and CEO
Since October 2025
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.6%
-
99.6%
-
99.7%
-
99.8%
-
99.8%
-
99.8%
Board connections
1 of this board's directors also sit on 1 other board.
- via Kathy Turner V
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $140,146
- 6 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Boekhorst Paul Francis Olivier Te Director, Officer (President and CEO) | Open-market purchase | +8,000 | $9.50 | $76,000 |
| Mar 20, 2026 | Michael F. Brigham Director | Option exercise | +25,000 | $5.84 | $146,000 |
| Mar 20, 2026 | Michael F. Brigham Director | Shares withheld for tax | −24,052 | $6.07 | $145,996 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier Te Director, Officer (President and CEO) | Open-market purchase | +2,556 | $5.00 | $12,780 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier Te Director, Officer (President and CEO) | Open-market purchase | +3,521 | $5.04 | $17,746 |
| Dec 2, 2025 | Boekhorst Paul Francis Olivier Te Director, Officer (President and CEO) | Open-market purchase | +3,708 | $4.87 | $18,058 |
| Nov 25, 2025 | David Scott Tomsche Director | Open-market purchase | +1,633 | $4.76 | $7,773 |
| Nov 25, 2025 | David Scott Tomsche Director | Open-market purchase | +1,633 | $4.77 | $7,789 |
| Jun 12, 2025 | Bryan K. Gathagan Director | Open-market purchase | +1,000 | $6.32 | $6,320 |
| Jun 11, 2025 | Gloria F. Basse Director | Option exercise | +3,530 | $4.81 | $16,979 |
| Aug 28, 2024 | David Scott Tomsche Director | Sold back to the company | +2,186 | $3.55 | $7,760 |
| Aug 23, 2024 | David Scott Tomsche Director | Sold back to the company | +6,005 | $3.55 | $21,318 |
| Aug 22, 2024 | David Scott Tomsche Director | Sold back to the company | +10,000 | $3.55 | $35,500 |
| Aug 19, 2024 | David Scott Tomsche Director | Sold back to the company | +3,172 | $3.67 | $11,641 |
| Aug 16, 2024 | David Scott Tomsche Director | Sold back to the company | +4,811 | $3.72 | $17,897 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.